Drug insight: rituximab in renal disease and transplantation (Q36577151)

15 August 2017

1 reference

title

Drug insight: rituximab in renal disease and transplantation (English)

1 reference

15 August 2017

1 reference

1 reference

Alan D Salama

1

1 reference

15 August 2017

Charles D Pusey

series ordinal

2

1 reference

15 August 2017

language of work or name

1 reference

1 April 2006

1 reference

Nature Clinical Practice Nephrology

15 August 2017

published in

1 reference

15 August 2017

volume

2

1 reference

15 August 2017

issue

4

1 reference

15 August 2017

page(s)

221-230

1 reference

Remission of chronic thrombotic thrombocytopenic purpura after treatment with cyclophosphamide and rituximab

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0133

Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0133

The relationship of FcgammaRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0133

7 January 2021

Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0133

7 January 2021

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0133

7 January 2021

B cell non-Hodgkin's lymphoma: rituximab safety experience

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0133

7 January 2021

Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0133

7 January 2021

Rituximab for reduction of anti-HLA antibodies in patients awaiting renal transplantation: 1. Safety, pharmacodynamics, and pharmacokinetics

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0133

7 January 2021

B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0133

7 January 2021

Rituximab for idiopathic membranous nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0133

7 January 2021

Rituximab in idiopathic membranous nephropathy: a one-year prospective study

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0133

7 January 2021

Anti-CD20 monoclonal antibody for the treatment of refractory autoimmune haemolytic anaemia associated with idiopathic membranous nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0133

7 January 2021

Change of the course of steroid-dependent nephrotic syndrome after rituximab therapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0133

7 January 2021

Rituximab induces remission in refractory HCV associated cryoglobulinaemic vasculitis

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0133

7 January 2021

Long-term effects of anti-CD20 monoclonal antibody treatment of cryoglobulinaemic glomerulonephritis

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0133

7 January 2021

Efficacy and safety of rituximab in type II mixed cryoglobulinemia

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0133

7 January 2021

Anti-CD20 monoclonal antibody (rituximab) treatment for hepatitis C-negative therapy-resistant essential mixed cryoglobulinemia with renal and cardiac failure

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0133

7 January 2021

Initial increase in the cryoglobulin level after rituximab therapy for type II cryoglobulinemia secondary to Waldenström macroglobulinemia does not indicate failure of response

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0133

7 January 2021

Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0133

7 January 2021

An open study of B lymphocyte depletion in systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0133

7 January 2021

Biopsy-verified response of severe lupus nephritis to treatment with rituximab (anti-CD20 monoclonal antibody) plus cyclophosphamide after biopsy-documented failure to respond to cyclophosphamide alone

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0133

7 January 2021

Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0133

7 January 2021

B lymphocyte depletion therapy in children with refractory systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0133

7 January 2021

Rituximab in childhood systemic lupus erythematosus refractory to conventional immunosuppression: case report

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0133

7 January 2021

Response of Wegener's granulomatosis to anti-CD20 chimeric monoclonal antibody therapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0133

7 January 2021

Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0133

7 January 2021

Rituximab induced remission in a patient with Wegener's granulomatosis.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0133

7 January 2021

Effective therapeutic use of rituximab in refractory Wegener's granulomatosis

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0133

7 January 2021

Nine patients with anti-neutrophil cytoplasmic antibody-positive vasculitis successfully treated with rituximab

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0133

7 January 2021

Rituximab for refractory Wegener's granulomatosis: report of a prospective, open-label pilot trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0133

7 January 2021

Lack of efficacy of rituximab in Wegener's granulomatosis with refractory granulomatous manifestations

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0133

7 January 2021

Anti-CD20 therapy of treatment-resistant Wegener's granulomatosis: favourable but temporary response.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0133

7 January 2021

Anti-CD20 monoclonal antibody (Rituximab) for life-threatening hemolytic-uremic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0133

7 January 2021

Successful treatment of severe thrombotic thrombocytopenic purpura with the monoclonal antibody rituximab

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0133

7 January 2021

Treatment of resistant thrombotic thrombocytopenic purpura with rituximab and cyclophosphamide

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0133

7 January 2021

Rituximab for chronic recurring thrombotic thrombocytopenic purpura: a case report and review of the literature

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0133

7 January 2021

Rituximab in the treatment of relapsed thrombotic thrombocytopenic purpura

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0133

7 January 2021

Efficiency of curative and prophylactic treatment with rituximab in ADAMTS13-deficient thrombotic thrombocytopenic purpura: a study of 11 cases

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0133

7 January 2021

Humanized anti-CD20 monoclonal antibody (Rituximab) treatment for post-transplant lymphoproliferative disorder

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0133

7 January 2021

Rapid response to rituximab in a pediatric liver transplant recipient with post-transplant lymphoproliferative disease and maintenance with sirolimus monotherapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0133

7 January 2021

New crossmatch technique eliminates interference by humanized and chimeric monoclonal antibodies

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0133

7 January 2021

Molecular heterogeneity in acute renal allograft rejection identified by DNA microarray profiling.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0133

7 January 2021

Refractory acute kidney transplant rejection with CD20 graft infiltrates and successful therapy with rituximab

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0133

7 January 2021

Rituximab as treatment for refractory kidney transplant rejection

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0133

7 January 2021

ABO incompatible kidney transplantations without splenectomy, using antigen-specific immunoadsorption and rituximab.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0133

7 January 2021

Plasmapheresis, CMV hyperimmune globulin, and anti-CD20 allow ABO-incompatible renal transplantation without splenectomy

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0133

7 January 2021

Successful A1-to-O ABO-incompatible kidney transplantation after a preconditioning regimen consisting of anti-CD20 monoclonal antibody infusions, splenectomy, and double-filtration plasmapheresis

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0133

7 January 2021

Preconditioning regimen consisting of anti-CD20 monoclonal antibody infusions, splenectomy and DFPP-enabled non-responders to undergo ABO-incompatible kidney transplantation

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0133

7 January 2021

A Comparison of splenectomy versus intensive posttransplant antidonor blood group antibody monitoring without splenectomy in ABO-incompatible kidney transplantation

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0133

7 January 2021

Overcoming a positive crossmatch in living-donor kidney transplantation.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0133

7 January 2021

Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0133

7 January 2021

Effect of anti-CD 20 antibody rituximab in patients with post-transplant lymphoproliferative disorder (PTLD).

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0133

7 January 2021

Rituximab (chimeric anti-CD20 antibody) for posttransplant lymphoproliferative disorder after solid organ transplantation in adults: long-term experience from a single center

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0133

7 January 2021

Rituximab treatment in patients with primary Sjögren's syndrome: an open-label phase II study

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0133

7 January 2021

Tolerability and safety of rituximab (MabThera).

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0133

7 January 2021

Treatment of vascular rejection with rituximab in cardiac transplantation

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0133

7 January 2021

Identifiers

DOI

10.1038/NCPNEPH0133

1 reference

15 August 2017

1 reference